Multidrug resistance and rhabdomyosarcoma (review)

Oncology Reports

Volumn 26, Issue 4, 2011, Pages 755-761

  Melguizo, Consolación ^a   Prados, Jose ^a   Rama, Ana R ^b   Ortiz, Raúl ^b   Álvarez, Pablo J ^a   Fernández, Juan E ^a   Aranega, Antonia ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF JAÉN   (Spain)

Author keywords

Differentiation; Multidrug resistance; Rhabdomyosarcoma

Indexed keywords

DNA TOPOISOMERASE; DOXORUBICIN; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CROSS RESISTANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; HUMAN; MOLECULAR PATHOLOGY; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANCE GENE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHABDOMYOSARCOMA; TUMOR DIFFERENTIATION;

ADOLESCENT; CHILD; DRUG RESISTANCE, MULTIPLE; HUMANS; RHABDOMYOSARCOMA; YOUNG ADULT;

EID: 79960749398     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1347     Document Type: Article

References (64)

1. Huh WW and Skapek SX: Childhood rhabdomyosarcoma: new insight on biology and treatment. Curr Oncol Rep 12: 402-410, 2010.
2. Crist WM, Anderson JR, Meza JL, et al: Intergroup rhabdomyosarcoma study-IV: results of patients with non-metastatic disease. J Clin Oncol 19: 3091-3102, 2001. (Pubitemid 32567502)
3. Newton WA Jr, Gehan EA, Webber BL, et al: Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification- an Intergroup Rhabdomyosarcoma Study. Cancer 76: 1073-1085, 1995.
4. Lawrence W Jr, Anderson JR, Gehan EA and Maurer H: Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup rhabdomyosarcoma Study Group. Children's cancer study group. Pediatric Oncology Group. Cancer 80: 1165-1170, 1997. (Pubitemid 27427618)
5. Crist WM, Garnsey L, Beltangady MS, et al: Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma committee. J Clin Oncol 8: 443-452, 1990. (Pubitemid 20087545)
6. Ferrari A, Miceli R, Meazza C, et al: Soft tissue sarcomas of childhood and adolescence: the prognostic role of tumor size in relation to patient body size. J Clin Oncol 27: 371-376, 2009.
7. Komdeur R, Klunder J, van der Graaf WT, van den Berg E, de Bont ES, Hoekstra HJ and Molenaar WM: Multidrug resistance proteins in rhabdomyosarcomas: comparison between children and adults. Cancer 97: 1999-2005, 2003. (Pubitemid 36397278)
8. Seitz G, Warmann SW, Vokuhl CO, Heitmann H, Treuner C, Leuschner I and Fuchs J: Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma. Pediatr Surg Int 23: 431-439, 2007. (Pubitemid 46626225)
9. Keshelava N, Seeger RC, Groshen S and Reynolds CP: Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 58: 5396-5405, 1998. (Pubitemid 28551122)
10. Ferrari A and Casanova M: Current chemotherapeutic strategies for rhabdomyosarcoma. Expert Rev Anticancer Ther 5: 283-294, 2005. (Pubitemid 40553093)
11. Singer S, Demetri GD, Baldini EH and Fletcher CD: Management of soft-tissue sarcomas: an overview and update. Lancet Oncol 1: 75-85, 2000.
12. Fulda S: Targeting apoptosis resistance in rhabdomyosarcoma. Curr Cancer Drug Targets 8: 536-544, 2008.
13. Bell DR, Gerlach JH, Kartner N, Buick RN and Ling V: Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J Clin Oncol 3: 311-315, 1985. (Pubitemid 15131998)
14. Ling V and Thompson LH: Reduced permeability in CHO cells as a mechanism of resistance to colchicines. J Cell Physiol 83: 103-116, 1973.
15. Oue T, Yoneda A, Uehara S, Yamanaka H and Fukuzawa M: Increased expression of multidrug resistance-associated genes after chemotherapy in pediatric solid malignancies. J Pediatr Sur 44: 77-80, 2009.
16. Li Y, Yuan H, Yang K, Xu W, Tang W and Li X: The structure and functions of P-glycoprotein. Curr Med Chem 17: 786-800, 2010.
17. Sharom JJ: ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 9: 105-127, 2008.
18. Ishikawa T, Kuo MT, Furuta K and Suzuki M: The human multidrug resistance-associated protein (MRP) gene family: from biological function to drug molecular design. Clin Chem Lab Med 38: 893-897, 2000.
19. Mirski SE, Gerlach JH and Cole SP: Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res 47: 2594-2598, 1987. (Pubitemid 17083146)
20. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP and Deeley RG: Overexpression of multidrug resistance associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54: 357-361, 1994. (Pubitemid 24053167)
21. Kruh GD and Belinsky MG: The MRP family of drug efflux pumps. Oncogene 22: 7537-7552, 2003. (Pubitemid 37487175)
22. Haimeur A, Conseil G, Deeley RG and Cole SP: The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5: 21-53, 2004. (Pubitemid 38294344)
23. Pituch-Noworolska A, Zaremba M and Wieczorek A: Expression of proteins associated with therapy resistance in rhabdomyosarcoma and neuroblastoma tumour cells. Pol J Pathol 60: 168-173, 2009.
24. Sun JR, Chan MC, Chang TY, Wang WY and Chiueh TS: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654, 1992.
25. Izquierdo MA, Scheffer GL, Flens MJ, et al: Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 148: 877-887, 1996. (Pubitemid 126660679)
26. Steiner E, Holzmann K, Elbling L, Micksche M and Berger W: Cellular functions of vaults and their involvement in multidrug resistance. Curr Drug Targets 7: 923-934, 2006.
27. Tan B, Piwnica-Worms D and Ratner L: Multidrug resistance transporters and modulation. Curr Opin Oncol 12: 450-458, 2000. (Pubitemid 32268882)
28. Scheffer GL, Schroeijers AB, Izquierdo MA, Wiemer EA and Scheper RJ: Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 12: 550-556, 2000. (Pubitemid 32039654)
29. Giles GI and Sharma RP: Topoisomerase enzymes as therapeutic targets for cancer chemotherapy. Med Chem 1: 383-394, 2005.
30. Ruiz-Gómez MJ, Souviron A, Martínez-Morillo M and Gil L: P-glycoprotein, glutathione and glutathione S-transferase increase in a colon carcinoma cell line by colchicines. J Physiol Biochem 56: 307-312, 2000. (Pubitemid 32216811)
31. Sau A, Pellizzari Tregno F, Valentino F, Federici G and Caccuri AM: Glutathione transferases and development of new principles to overcome drug resistance. Arch Biochem Biophys 500: 116-122, 2010.
32. Crist W, Gehan EA, Ragab AH, et al: The third intergroup rhabdomyosarcoma study. J Clin Oncol 13: 610-630, 1995.
33. Tsokos M, Webber BL, Parham DM, et al: Rhabdomyosarcoma. A new classification scheme related to prognosis. Arch Pathol Lab Med 116: 847-855, 1992.
34. Reboul-Marty J, Quintana E, Mosseri V, Flamant F, Asselain B, Rodary C and Zucker JM: Prognostic factors of alveolar rhabdomyosarcoma in childhood. An International Society of Pediatric Oncology study. Cancer 68: 493-498, 1991.
35. Chan HS, Thorner PS, Haddad G and Ling V: Immunohistochemical detection of P-glycoprotein-prognostic correlation in soft-tissue sarcoma of the childhood. J Clin Oncol 8: 689-704, 1990. (Pubitemid 20127254)
36. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE and Gottesman MM: P-glycoprotein: from genomics to mechanism. Oncogene 22: 7468-7685, 2003.
37. Kuttesch JF, Parham DM, Luo X, et al: P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J Clin Oncol 14: 886-900, 1996. (Pubitemid 26085534)
38. Klunder JW, Komdeur R, Van Der Graaf WT, et al: Expression of multidrug resistance-associated proteins in rhabdomyosarcomas before and after chemotherapy: the relationship between lung resistance-related protein (LRP) and differentiation. Hum Pathol 34: 150-155, 2003. (Pubitemid 36258806)
39. Molenaar WM, Oosterhuis JW and Kamps WA: Cytologic differentiation in childhood rhabdomyosarcomas following polychemotherapy. Hum Pathol 15: 973-979, 1984. (Pubitemid 15130387)
40. Leuschner I, Harms D, Mattke A, Koscielniak E and Treuner J: Rhabdomyosarcoma of the urinary bladder and vagina: a clinicopathologic study with emphasis on recurrent disease: a report from the Kiel Pediatric Tumor Registry and the German CWS Study. Am J Surg Pathol 25: 856-864, 2001. (Pubitemid 32594978)
41. Molenaar WM, Oosterhuis JW, Oosterhuis AM and Ramaekers FC: Mesenchymal and muscle-specific intermediate filaments (vimentin and desmin) in relation to differentiation in childhood rhabdomyosarcomas. Hum Pathol 16: 838-843, 1985.
42. d'Amore ES, Tollot M, Stracca-Pansa V, Menegon A, Meli S, Carli M and Ninfo V: Therapy associated differentiation in rhabdomyosarcomas. Mod Pathol 7: 69-75, 1994.
43. Prados J, Melguizo C, Fernández A, Aránega AE, Alvarez L and Aránega A: Inverse expression of MDR1 and c-myc genes in a rhabdomyosarcoma cell line resistant to actinomycin D. J Pathol 180: 85-89, 1996. (Pubitemid 26348897)
44. Melguizo C, Prados J, Fernández JE, Vélez C, Alvarez L and Aránega A: Actinomycin D causes multidrug resistance and differentiation in a human rhabdomyosarcoma cell line. Cell Mol Biol 40: 137-145, 1994.
45. Scheper RJ, Broxterman HJ, Scheffer GL, et al: Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoproteinmediated multidrug resistance. Cancer Res 53: 1475-1479, 1993. (Pubitemid 23113213)
46. Izquierdo MA, Shoemaker RH, Flens MJ, Scheffer GL, Wu L, Prather TR and Scheper RJ: Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer 65: 230-237, 1996. (Pubitemid 26051685)
47. Kolfschoten GM, Hulscher TM, Pinedo HM and Boven E: Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts. Br J Cancer 83: 921-927, 2000.
48. Kitazono M, Sumizawa T, Takebayashi Y, et al: Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 91: 1647-1653, 1999. (Pubitemid 29479932)
49. Cocker HA, Hobbs SM, Tiffin N, Pinkerton CR and Kelland LR: High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance. Br J Cancer 85: 1746-1752, 2001. (Pubitemid 34081522)
50. Taylor AC, Shu L, Danks MK, et al: P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol 35: 96-103, 2000.
51. Peng Y, Chen L, Li C, Lu W, Agrawal S and Chen J: Stabilization of MDM2 oncoprotein by mutant p53. J Biol Chem 276: 6874-6878, 2001.
52. Sola JE, Wojno KJ, Dooley W and Colombani PM: P-glycoprotein status of favorablehistology Wilms' tumor predicts treatment outcome. J Pediatr Surg 29: 1080-1083, 1994.
53. Warmann SW, Heitmann H, Teichmann B, Gratz KF, Ruck P, Hunger M and Fuchs J: Effects of Pglycoprotein modulation on the chemotherapy of xenotransplanted human hepatoblastoma. J Pediatr Surg 22: 373-386, 2005. (Pubitemid 40993600)
54. Norris MD, Burkhart CA, Marshall GM, Weiss WA and Haber M: Expression of N-myc and MRP genes and their relationship to N-myc gene dosage and tumor formation in a murine neuroblastoma model. Med Pediatr Oncol 35: 585-589, 2000.
55. de Cremoux P, Jourdan-Da-Silva N, Couturier J, et al: Role of chemotherapy resistance genes in outcome of neuroblastoma. Pediatr Blood Cancer 48: 311-317, 2007.
56. Asmar L, Gehan EA, Newton WA, et al: Agreement among and within groups of pathologists in the classification of rhabdomyosarcoma and related childhood sarcomas. Report of an international study of four pathology classifications. Cancer 74: 2579-2588, 1994. (Pubitemid 24320865)
57. Newton WA Jr, Soule EH, Hamoudi AB, Reiman HM, Shimada H, Beltangady M and Maurer H: Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: clinicopathologic correlation. J Clin Oncol 6: 67-75, 1998.
58. Barr FG: Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Surg 19: 483-491, 1998.
59. Marchal JA, Prados J, Melguizo C, et al: GR-891: a novel 5-fluorouracil acyclonucleoside prodrug for differentiation therapy in rhabdomyosarcoma cells. Br J Cancer 79: 807-813, 1999. (Pubitemid 29082109)
60. Prados J, Melguizo C, Marchal JA, Vélez C, Alvarez L and Aránega A: Therapeutic differentiation in a human rhabdomyosarcoma cell line selected for resistance to actinomycin D. Int J Cancer 75: 379-383, 1998. (Pubitemid 28100039)
61. Leuschner I, Heuer T and Harms D: Induccion of drug resistance in human rhabdomyosarcoma cell lines is associated with increased maturation: possible explanation for differentiation in recurrences? Pediatr Dev Pathol 5: 276-282, 2002. (Pubitemid 34712242)
62. Staibano S, Franco R, Tranfa F, et al: Orbital rhabdomyosarcoma: relationship between DNA ploidy, p53, bcl-2, MDR-1 and Ki67 (MIB1) expression and clinical behavior. Anticancer Res 24: 249-257, 2004. (Pubitemid 38279715)
63. Prados J, Melguizo C, Fernández JE, et al: Induction of drug resistance in embryonal rhabdomyosarcoma treated with conventional chemotherapy is associated with HLA class I increase. Neoplasma 53: 226-231, 2006. (Pubitemid 43844381)
64. Melguizo C, Prados J, Marchal JA, et al: Modulation of HLA class I expression in multidrug-resistant human rhabdomyosarcoma cells. Neoplasma 50: 91-96, 2003. (Pubitemid 36560041)